Testing Ramipril to Prevent Memory Loss in People With Glioblastoma
Status:
Recruiting
Trial end date:
2022-09-30
Target enrollment:
Participant gender:
Summary
This study is to determine if an oral drug called Ramipril can lower the chance of memory
loss in patients with glioblastoma getting chemoradiation. Patients will take Ramipril during
chemoradiation and continue until 4 months post-treatment. Memory loss will be assessed using
several neurocognitive tests throughout the duration of the study.